Biofrontera AG, of Leverkusen, Germany, reported data from three pivotal phase III trials in which lead candidate, BF-200 ALA, demonstrated patient clearance rates of 85 percent to 91 percent in the topical treatment of actinic keratosis, a superficial skin cancer caused by sun damage.